AANS/CNS Cerebrovascular Section and American Society of Stereotactic and Functional Neurosurgery Contribute to SNS Neurosurgeon-Scientist Training Program

The Cerebrovascular Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons and the American Society for Stereotactic and Functional Neurosurgery joined in supporting the Society of Neurological Surgeons newly launched Neurosurgeon-Scientist Training Program.

Unraveling the biology behind aggressive pediatric brain tumor reveals potential new treatment avenue

Researchers at the University of Michigan Rogel Cancer Center have identified a novel treatment approach to an aggressive type of pediatric brain cancer, using therapies already approved to treat cancer. The team developed a mouse model of pediatric glioma with a histone mutation called H3.3-G34, which allowed them to study the tumor’s biology in the presence of a functional immune system, revealing a promising outlook for long-term survival.

Henry Ford Health + MSU Health Sciences Funds Five Cancer Research Grants to Advance Cancer Medicine, Combat Health Disparities

Henry Ford Health + Michigan State University Health Sciences today announced its funding of five cancer research grants of up to $100,000 each. These five grants follow an initial wave of funding from the partnership, in which 18 pilot grants of up to $25,000 each were funded in May 2022.

MD Anderson to host virtual Cancer Neuroscience Symposium

MD Anderson will host the virtual Cancer Neuroscience Symposium Sept. 22-23, 2022, in collaboration with the journal Advanced Biology. The symposium is free to attend and gathers leading experts in the field to discuss a variety of topics on the relationship between cancer biology and neuroscience. Registration includes the opportunity to participate in an abstract competition and to view sessions following the event.

Sylvester Leads Study on New Treatment Option for Brain Tumor that Relapses or Fails to Respond to Standard of Care

Taken twice daily, oral olutasidenib helped to stabilize relapsed or refractory gliomas in heavily pretreated patients with less toxicity than standard of care treatment, according to a study led by Sylvester Comprehensive Cancer Center at the University of Miami School…

Noninvasive Brain Tumor Treatment Allows Physicians to treat tumors with Pinpoint Accuracy

Joseph P. Weiner, MD, radiation oncologist at Rutgers Cancer Institute and assistant professor of radiation oncology at Rutgers Robert Wood Johnson Medical School, who specializes in malignant and benign cancers of the brain and spine shares more about Gamma knife, a non-surgical treatment option that uses high doses of precisely focused radiation beams to destroy cancer cells and non-cancerous tumors.

Study Sheds Light on Mechanism of Liposome Accumulation in Tumors

Dmitri Simberg, PhD, associate professor in the University of Colorado Skaggs School of Pharmacy, released a new study of the effectiveness of different types of fluorescent labels used to monitor the accumulation of liposomes in tumors. The study was published on July 1, 2021, in ACS Nano.

New immunotherapy target discovered for malignant brain tumors

Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumors, which so far have resisted the ground-breaking cancer treatment based on harnessing the body’s immune system. The discovery, reported in the journal CELL, emerged from laboratory experiments and has no immediate implications for treating patients.

Ingo Mellinghoff Named Chair of MSK’s Department of Neurology

Neuro-oncologist and renowned physician-scientist Ingo Mellinghoff will lead MSK’s distinguished Department of Neurology after previously serving as Acting Co-Chair.

Rutgers Cancer Institute Researchers Utilize 4D Printing with Patient Derived Organoids to Accelerate Treatment Testing for Common Brain Tumor

Rutgers Cancer Institute investigator shares about a new project in which 4-dimensional (4D) printing of arrays that transform from cell-culture inserts into histological cassettes are utilized and hold patient tissue samples for rapid programmable drug testing to accelerate treatment testing for glioblastoma multiforme (GBM), a common brain tumor.

Brain Cancer: UVA IDs Gene Responsible for Deadly Glioblastoma

The discovery of the oncogene responsible for glioblastoma could be the brain tumor’s Achilles’ heel, one researcher says.

Bridging the gap between AI and the clinic Rapprocher l’IA de la pratique clinique

Researchers trained machine learning algorithms on data from more than 62,000 patients with a meningioma. Their goal was to find statistical associations between malignancy, survival, and a series of basic clinical variables including tumour size, tumour location, and surgical procedure.

Des chercheurs ont entraîné des algorithmes d’apprentissage automatique à partir des données de plus de 62 000 patients ayant un méningiome. L’objectif était de déceler des associations statistiques entre la malignité, le temps de survie et d’autres variables cliniques de base telles que la taille de la tumeur, son emplacement et la nature de l’intervention chirurgicale effectuée.

Zika Virus’ Key into Brain Cells ID’d, Leveraged to Block Infection and Kill Cancer Cells

Two different UC San Diego research teams identified the same molecule — αvβ5 integrin — as Zika virus’ key to brain cell entry. They found ways to take advantage of the integrin to both block Zika virus from infecting cells and turn it into something good: a way to shrink brain cancer stem cells.

First Molecular Test in US to Better Detect Brain Tumors Now Available to Patients

NYU Langone Health and its Perlmutter Cancer Center have launched clinical whole genome DNA methylation profiling for patients with brain tumors.
This leading-edge molecular assay utilizes DNA epigenetic signatures and artificial intelligence with machine learning to correctly identify and subtype brain tumors. NYU Langone Health is the first Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in the United States to receive state approval (New York State Department of Health) for whole genome DNA methylation for diagnosis and classification of brain tumors.

Sibling Bond Gets Brother with Large Brain Tumor the Best Care

When Gary Colon, 51, of Miami, Florida suddenly had trouble speaking, he called his sister, Becky, of Stratford, Connecticut for help. She urged him to go to an emergency department, where he had tests that revealed a meningioma. This large brain tumor was indenting and injuring the speech area of his brain.

Becky quickly made arrangements for Gary to come home and have brain surgery at Norwalk Hospital, where she’s worked for 17 years and knew he would get the best care.

Norwalk Hospital is equipped to handle these types of brain surgery cases because of the highly trained neurosurgeons, and seasoned physician assistants, nurses, medical assistants, operating room staff, and intensive care unit staff who work so well together.

CNS Gift to the CNS Foundation Doubles Innovative Clinical Research Initiative, Creating Annual NINDS/CNSF K12 Scholar Awards

The Congress of Neurological Surgeons Foundation (CNS Foundation) announced a second K12 award will be funded by a generous gift from the Congress of Neurological Surgeons (CNS). The award is made possible through a collaboration with the Foundation of the National Institutes of Health (FNIH) and the National Institutes of Health (NIH).